AI Radiomics Market Size and Share Analysis - Growth Trends and Forecasts (2026-2033)

Market Size and Trends

The AI Radiomics market is estimated to be valued at USD 1.2 billion in 2026 and is expected to reach USD 3.5 billion by 2033, growing at a compound annual growth rate (CAGR) of 16.5% from 2026 to 2033. This significant growth highlights the increasing adoption of AI-driven imaging analytics in healthcare, driven by advancements in machine learning algorithms and expanding applications across oncology, neurology, and cardiology diagnostics.

Current market trends emphasize the integration of AI radiomics with big data and cloud computing to enhance diagnostic accuracy and personalized treatment plans. Additionally, rising investments in AI healthcare startups and regulatory approvals of AI-based diagnostic tools are fueling innovation. The trend towards non-invasive, cost-effective imaging solutions combined with growing demand for precision medicine further accelerates the market's rapid expansion and technological evolution.

Segmental Analysis:

By Modality: Dominance of Computed Tomography (CT) Driven by Imaging Precision and Clinical Versatility

In terms of By Modality, Computed Tomography (CT) contributes the highest share of the AI Radiomics market owing to its exceptional capability in producing high-resolution, cross-sectional images that provide detailed anatomical information. CT's rapid image acquisition combined with its wide availability in clinical settings makes it an indispensable tool for various diagnostic and therapeutic applications. The integration of AI in CT imaging allows for enhanced image reconstruction, quantitative analysis, and feature extraction, which improves lesion characterization, treatment planning, and disease monitoring. Moreover, CT's role in emergent medical scenarios such as trauma and cardiovascular diagnostics fuels its extensive use. The modality's compatibility with AI-powered radiomics algorithms supports automated detection and classification of abnormalities, thus reducing radiologist workloads and improving diagnostic accuracy. The increasing demand for non-invasive but highly accurate imaging solutions further propels the adoption of AI-based CT radiomics. Additionally, advancements in CT technology, including spectral CT and dual-energy imaging, enrich data quality, enabling AI models to detect subtle tissue heterogeneity and microstructural changes more effectively. Overall, CT's proven efficacy, speed, and extensive clinical applications establish it as the leading segment within AI radiomics modalities.

By Application: Oncology Leading Growth Due to Precision Medicine and Early Detection

Oncology emerges as the primary contributor to the AI Radiomics market by Application, driven by the critical need for personalized cancer diagnosis, prognosis, and treatment response assessment. Cancer management benefits immensely from radiomics, which transforms medical images into high-dimensional quantitative data offering insights beyond visual interpretation. AI-powered radiomics facilitates tumor heterogeneity analysis, enabling oncologists to differentiate malignant from benign lesions and predict tumor aggressiveness with greater accuracy. This precision assists in tailoring individualized treatment strategies, thereby optimizing clinical outcomes. The increasing prevalence of cancer globally, coupled with the growing emphasis on early detection and minimally invasive diagnostics, significantly supports oncology's dominance. Radiomics applications in identifying biomarkers for immunotherapy and chemotherapy response prediction are also expanding, providing crucial information for decision-making. Furthermore, oncology-focused clinical trials increasingly incorporate AI radiomics for patient stratification and monitoring, thereby accelerating research and validation. The integration of multimodal imaging datasets such as CT, MRI, and PET enhances the comprehensiveness of radiomic analyses in oncology. As a result, oncology's dynamic clinical demands and the transformative potential of AI radiomics in improving diagnostic precision and therapeutic efficacy solidify its position as the foremost application segment.

By End User: Hospitals & Clinics Leading Growth Fueled by Clinical Integration and Patient Care Optimization

Hospitals & Clinics contribute the largest share in AI Radiomics by End User, driven primarily by their frontline role in patient diagnosis and treatment. These healthcare settings are increasingly adopting AI radiomics to enhance diagnostic workflows, reduce interpretation times, and enable more accurate decision-making, particularly in complex cases. Integration of AI-powered radiomic tools in routine clinical practice supports non-invasive disease characterization, prognosis, and personalized treatment planning, which align closely with hospitals' goals of improving patient outcomes and operational efficiency. Hospitals and clinics benefit from their access to diverse patient populations and extensive imaging databases, facilitating continuous AI model training and refinement. The growing trend toward multidisciplinary care approaches emphasizes data-driven insights, where radiomics plays a crucial role in bridging imaging and clinical data. Moreover, rising investments in digital infrastructure and AI-enabled medical devices in hospitals empower broader adoption of radiomic applications. The demand for reducing diagnostic errors and enhancing early disease detection further catalyzes market growth in this segment. Collaborations with research institutes and pharmaceutical companies also enable hospitals to leverage radiomics for clinical trials and drug development, expanding their capabilities beyond standard care. Hence, the strategic integration of AI radiomics into hospital and clinic workflows positions this end user segment as the primary growth driver in the market.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the AI Radiomics market is driven by a highly mature healthcare infrastructure, strong research and development capabilities, and significant investment from both government and private sectors. The region benefits from the presence of leading technology firms and medical imaging companies that actively integrate AI into radiomics for cancer diagnosis, prognosis, and treatment planning. Robust regulatory frameworks, such as FDA approvals for AI-based diagnostic tools, foster innovation and adoption. The US and Canada host several renowned institutions and startups that contribute to cutting-edge advancements, including IBM Watson Health, GE Healthcare, and Philips Healthcare. Additionally, extensive collaborations between academia and industry fuel continuous improvement in AI radiomics technologies.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the AI Radiomics market, propelled by rapidly advancing healthcare infrastructure, rising government initiatives focused on AI integration, and increasing demand for cost-effective diagnostic solutions in emerging economies. Countries such as China, Japan, South Korea, and India are investing heavily in AI healthcare research, bolstered by favorable policies and expanding medical imaging sectors. The growing presence of multinational companies partnering with local players accelerates technology transfer and market penetration. For instance, companies like Siemens Healthineers and Tencent Healthcare are leveraging local market expertise and government backing to expand their product offerings. Furthermore, rising healthcare awareness and increasing incidence of chronic diseases enhance the necessity for advanced AI-enabled radiomics.

AI Radiomics Market Outlook for Key Countries

United States

The United States' market is at the forefront of AI Radiomics with a robust ecosystem comprising top-tier research institutions, advanced healthcare systems, and a favorable regulatory environment. Major players such as IBM Watson Health, GE Healthcare, and Zebra Medical Vision drive significant innovations. The country's emphasis on precision medicine and new payment models encourages early adoption of AI-driven diagnostic tools, ensuring continuous growth in AI radiomics applications across oncology and other critical disease areas.

China

China's market growth is propelled by strong government initiatives supporting AI in healthcare, including substantial funding for digitization and health tech innovation. Local companies like Infervision and Yitu Healthcare are expanding their AI radiomics capabilities, focusing on scalable solutions tailored to the vast patient base. Partnerships between international and domestic firms facilitate rapid technology deployment, while growing hospital networks and increasing access to advanced imaging devices bolster market demand.

Japan

Japan continues to lead in technological innovation, particularly in integrating AI with medical imaging hardware developed by domestic giants like Canon Medical Systems and Fujifilm. The country's aging population drives demand for efficacious cancer diagnostics, boosting AI radiomics adoption. Government support through health technology policies and reimbursement frameworks helps accelerate the deployment of AI tools in clinical settings, enhancing patient outcomes and operational efficiencies.

Germany

Germany's market benefits from a strong healthcare infrastructure combined with rigorous data protection regulations that shape the adoption of AI radiomics. Industry leaders such as Siemens Healthineers and Brainlab play pivotal roles in developing AI-integrated imaging platforms. The collaborative ecosystem between research centers, hospitals, and industry enhances innovation while ensuring compliance with stringent European standards, positioning Germany as a key player in the European AI radiomics landscape.

India

India presents a rapidly expanding AI Radiomics market, characterized by increasing government focus on digital health initiatives and affordable healthcare delivery. Companies like Niramai and Qure.ai are innovating AI solutions tailored for local healthcare challenges, including early cancer detection with limited resources. The growing adoption of cloud computing and AI platforms by healthcare providers, coupled with a large pool of data and rising awareness, creates a fertile environment for AI radiomics market growth.

Market Report Scope

Market Segmentation

Modality Insights (Revenue, USD, 2021 - 2033)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Positron Emission Tomography (PET)
• Ultrasound
• Others

Application Insights (Revenue, USD, 2021 - 2033)

• Oncology
• Neurology
• Cardiology
• Pulmonology
• Others

End User Insights (Revenue, USD, 2021 - 2033)

• Hospitals & Clinics
• Diagnostic Imaging Centers
• Pharmaceutical & Biotechnology Companies
• Research Institutes
• Others

Regional Insights (Revenue, USD, 2021 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Siemens Healthineers
• GE Healthcare
• Philips Healthcare
• IBM Watson Health
• Canon Medical Systems
• Fujifilm Holdings
• Qure.ai Technologies
• Aidence BV
• Vayyar Imaging
• Nvidia Corporation